<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132588" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Difelikefalin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pilla</surname>
            <given-names>Julianne E.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Devulapally</surname>
            <given-names>Pavan</given-names>
          </name>
          <aff>Methodist hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Julianne Pilla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pavan Devulapally declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132588.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Difelikefalin is a medication used to treat and manage uremic pruritis and postoperative pain, affecting patients' quality of life. Difelikefalin is in the opioid class of drugs and works as a selective kappa-opioid receptor agonist; alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, CKD-943, MR13A9, FE202845, and CR 845. Since difelikefalin is peripherally selective, it is unlikely to cause lethal central nervous system&#x000a0;adverse effects such as respiratory depression. IV dosing schedule after dialysis sessions enhances treatment logistics and patient outcomes. Moreover, difelikefalin presents as a safer alternative for managing postoperative pain amid the opioid crisis, offering decreased abuse potential and promising results in early trials. However, further research is needed to validate its efficacy and safety, especially in patients with diabetes and end-stage renal disease. This activity describes the mechanism of action, indications, administration, adverse effects, monitoring, and contraindications for difelikefalin therapy pertinent for interprofessional team members in treating patients&#x000a0;with uremic pruritis or postoperative pain.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with uremic pruritus and post-operative pain who may benefit from difelikefalin therapy.</p></list-item><list-item><p>Screen patients for contraindications, potential drug interactions, and other factors that may impact the safe and effective use of difelikefalin.</p></list-item><list-item><p>Assess the effectiveness of difelikefalin therapy in managing uremic pruritus and postoperative pain, monitoring treatment response, and adjusting the treatment plan as needed.</p></list-item><list-item><p>Collaborate with other healthcare professionals, such as nephrologists, anesthesiologists, and pain management specialists, to ensure coordinated care and optimize the use of difelikefalin in managing uremic pruritus and post-operative pain.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132588&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132588">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-132588.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The use of opioid medication for analgesia dates back to the 1800s. One of the original opioid medications, morphine, named after Morpheus, the god of dreams, was extracted from opium plants and injected intravenously (IV) to provide analgesia in patients suffering from neuralgia. In the 1990s, various extended-release oral opioid formulations were introduced to the market.</p>
        <p>These oral formulations made available in high doses marked the beginning of the opioid crisis in the United States today. When&#x000a0;combined with tolerance and lethal central nervous system (CNS) adverse effects, the euphoric effects of these medications pose a dangerous situation for patients seeking pain relief. The opioid crisis has made the transition to illegal drug use and death by overdose, with oral formulations, commonplace. In the United States, in 2016, over 230 million opioid prescriptions were written to treat acute and chronic pain. The&#x000a0;survey showed that&#x000a0;1 in every&#x000a0;3 Americans had been prescribed an opioid medication. Safe and effective pain management remains challenging for the clinician&#x000a0;and interprofessional healthcare team. The market for novel opioid medications with less abuse potential and fewer dangerous&#x000a0;adverse effects is vast.<xref ref-type="bibr" rid="article-132588.r1">[1]</xref><xref ref-type="bibr" rid="article-132588.r2">[2]</xref></p>
        <p>Kappa, delta, and mu-opioid receptors are present in various human tissues and can be targeted in treating acute and chronic pain. Opioid receptor distribution in patients with end-stage renal disease requiring hemodialysis plays a role in the chronic itch that they can experience.<xref ref-type="bibr" rid="article-132588.r3">[3]</xref> Polypharmacy is commonly involved in managing these patients, who often have many comorbidities and decreased quality of life. The potential for selective opioid medications to target specific receptors in peripheral tissues is groundbreaking, and it offers the opportunity to treat the etiology of itch that patients with end-stage renal disease may suffer from.&#x000a0;</p>
        <p>Difelikefalin&#x000a0;is indicated&#x000a0;for treating moderate-to-severe pruritus associated with chronic kidney disease in&#x000a0;adults undergoing hemodialysis&#x000a0;and is FDA-approved for that purpose.<xref ref-type="bibr" rid="article-132588.r1">[1]</xref><xref ref-type="bibr" rid="article-132588.r4">[4]</xref><xref ref-type="bibr" rid="article-132588.r5">[5]</xref>&#x000a0; In phase&#x000a0;3 clinical trials,&#x000a0;IV difelikefalin&#x000a0;showed analgesic efficacy in treating post-operative pain and uremic pruritus in patients with end-stage renal disease who require hemodialysis.<xref ref-type="bibr" rid="article-132588.r5">[5]</xref><xref ref-type="bibr" rid="article-132588.r6">[6]</xref><xref ref-type="bibr" rid="article-132588.r1">[1]</xref>&#x000a0;Phase&#x000a0;2 clinical trials&#x000a0;examining off-label utilization of difelikefalin for notalgia paresthetica and paroxysmal neuropathic pruritus in pediatric&#x000a0;patients with Type I Chiari&#x000a0;malformations suggest the utility of the kappa opioid receptor&#x000a0;for pruritis of neuropathic etiology.<xref ref-type="bibr" rid="article-132588.r7">[7]</xref><xref ref-type="bibr" rid="article-132588.r8">[8]</xref></p>
      </sec>
      <sec id="article-132588.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Difelikefalin is a selective kappa-opioid receptor agonist. Alternative names for difelikefalin include 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid,&#x000a0; KORSUVA, CKD-943, MR13A9, FE202845, and CR 845.<xref ref-type="bibr" rid="article-132588.r4">[4]</xref><xref ref-type="bibr" rid="article-132588.r9">[9]</xref>&#x000a0;Difelikefalin is peripherally selective due to its small hydrophilic peptide structure.&#x000a0;This drug is not able to cross the blood-brain barrier. Therefore, unlike&#x000a0;many other opioid medications, it does not cause&#x000a0;lethal&#x000a0;CNS adverse effects such as respiratory depression.<xref ref-type="bibr" rid="article-132588.r10">[10]</xref>&#x000a0;</p>
        <p>Difelikefalin has no action at the mu-opioid receptor, which is responsible for the euphoric effects of traditional opioid medications. Without activity at the mu-opioid receptors in the CNS, negligible abuse potential is apparent for this novel agent.<xref ref-type="bibr" rid="article-132588.r9">[9]</xref>&#x000a0;This medication&#x000a0;selectively acts on kappa opioid receptors in peripheral tissues, contributing to pruritis and nociception. Activating opioid receptors in peripheral neurons and keratinocytes reduces afferent (sensory) impulses toward the CNS, decreasing pain signals. Activating kappa&#x000a0;opioid&#x000a0;receptors on immune cells, including monocytes and T lymphocytes, decreases the release of pro-inflammatory chemicals such as prostaglandins.<xref ref-type="bibr" rid="article-132588.r11">[11]</xref><xref ref-type="bibr" rid="article-132588.r12">[12]</xref><xref ref-type="bibr" rid="article-132588.r13">[13]</xref></p>
      </sec>
      <sec id="article-132588.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Difelikefalin can be administered via the oral or IV route. IV dosing is weight-based.<xref ref-type="bibr" rid="article-132588.r11">[11]</xref><xref ref-type="bibr" rid="article-132588.r10">[10]</xref>&#x000a0;IV dosings and administration for uremic pruritus:</p>
        <list list-type="bullet">
          <list-item>
            <p>0.5 mcg per kg IV bolus into the venous port of the dialysis circuit immediately following dialysis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Weight-based dosing in the treatment of uremic pruritus should be taken into careful consideration when rendering this medication. The appropriate weight-based dose is determined by the clinician and is based on the prescription dry body weight of the patient with end-stage renal disease, where the patient is considered normovolemic.<xref ref-type="bibr" rid="article-132588.r11">[11]</xref><xref ref-type="bibr" rid="article-132588.r14">[14]</xref><xref ref-type="bibr" rid="article-132588.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Difelikefalin&#x000a0;showed a dose-proportional response over a single dosage range from 1 to 3 mcg/kg and multiple&#x000a0;IV dosage range from 0.5 to 2.5 mcg/kg in chronic kidney disease patients undergoing hemodialysis. A steady-state plasma concentration was reached after the second administered dosage, and the mean accumulation ratio was up to 1.6.</p>
        <list list-type="bullet">
          <list-item>
            <p>Bioavailability: 100%</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Distribution: The mean volume of distribution is approximately 238 mL/kg, and human plasma protein binding in dialysis patients is 23% to 28%.<xref ref-type="bibr" rid="article-132588.r15">[15]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolism: Not metabolized by cytochrome P450 (CYP) enzymes presents in human hepatic microsomes CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A or in in-vitro hepatocytes; excreted unchanged in urine and bile.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Elimination half-life: 2 hours</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Duration of action: 12 hours after a single IV dose<xref ref-type="bibr" rid="article-132588.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patients Population&#x000a0;</bold>
</p>
        <p><bold>Hepatic impairment: </bold>No dose adjustment is&#x000a0;necessary for patients with mild-to-moderate hepatic impairment. However, the impact of the pharmacokinetics of difelikefalin has&#x000a0;not been evaluated in patients with severe hepatic impairment; therefore, the use of difelikefalin is not recommended in this patient population.&#x000a0;</p>
        <p><bold>Renal impairment:</bold>&#x000a0;The manufacturer label provides no dose adjustment data for patients with&#x000a0;renal impairment.&#x000a0;Difelikefalin has not been studied in patients on peritoneal dialysis and&#x000a0;has no recommendations for use in this patient population.</p>
        <p><bold>Pregnant women: </bold>Difelikefalin&#x000a0;is considered a pregnancy category&#x000a0;B medicine. Limited data on the use of difelikefalin in pregnant women is insufficient to assess a drug-associated risk for significant congenital disabilities or miscarriage.</p>
        <p><bold>Breastfeeding women: </bold>The manufacturer labels do not provide data&#x000a0;regarding the presence of difelikefalin in human milk, its effects on the breastfed infant, and/or milk production.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The safety and efficacy of&#x000a0;difelikefalin&#x000a0;are not established in pediatric patients.&#x000a0;</p>
        <p><bold>Older patients:&#x000a0;</bold>The safety and efficacy of&#x000a0;difelikefalin&#x000a0;were&#x000a0;studied on&#x000a0;848 subjects in the placebo-controlled trial.<xref ref-type="bibr" rid="article-132588.r16">[16]</xref> In this study,&#x000a0;278 subjects (32.8%) and 98 subjects (11.6%) were 65 and 75 years of age or older, respectively. No&#x000a0;overall differences in the safety or&#x000a0;efficacy of difelikefalin have been observed between&#x000a0;older and adult patient populations. The incidence of somnolence was 7% higher in&#x000a0;older&#x000a0;patients than in adult patients.&#x000a0;No difference in plasma concentrations of&#x000a0;difelikefalin has been observed between older and adult patient populations.</p>
      </sec>
      <sec id="article-132588.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Phase&#x000a0;3 clinical trials involving patients with end-stage renal disease requiring dialysis suffering from uremic pruritus&#x000a0;involved a study design. Patients received&#x000a0;IV difelikefalin at weight-based doses of 1.0 mcg per kg&#x000a0;3 times a week in the venous circuit of their dialysis machine for&#x000a0;12 weeks.<xref ref-type="bibr" rid="article-132588.r5">[5]</xref> This study demonstrated&#x000a0;the following most common adverse effects:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vomiting</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dizziness</p>
          </list-item>
        </list>
        <p>A double-blind, randomized study assessed the potential of difelikefalin to cause respiratory depression in healthy patients compared to a placebo. The lowest observed respiratory rate in study subjects in both groups was 14 breaths per minute. This respiratory rate is well above the 10 breaths per minute, which qualified as respiratory depression for this study. Additionally, no significant differences in pulse oximetry readings were observed in subjects receiving placebo versus those receiving IV difelikefalin. This study utilized supratherapeutic&#x000a0;IV doses of 1.0 and 5.0 mcg per kg.<xref ref-type="bibr" rid="article-132588.r10">[10]</xref> The following adverse effects were reported in 20% to 60% of participants:</p>
        <list list-type="bullet">
          <list-item>
            <p>Paresthesia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypoesthesia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Somnolence</p>
          </list-item>
        </list>
        <p>When study subjects experienced these adverse effects, the persistence of the symptoms ranged from less than&#x000a0;1 minute to less than&#x000a0;90 minutes and did not require any intervention.<xref ref-type="bibr" rid="article-132588.r10">[10]</xref></p>
      </sec>
      <sec id="article-132588.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>No published contraindications exist for difelikefalin. Phase&#x000a0;3 clinical trials involved patients with comorbidities and polypharmacy, demonstrating promise for difelikefalin to have generalized applicability with low risk for drug-drug interactions. Difelikefalin does not interfere with liver enzymes.<xref ref-type="bibr" rid="article-132588.r11">[11]</xref>&#x000a0;Of note, clinical trials have only included adult patients.&#x000a0;Difelikefalin should not be administered to children or adolescents.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>
<bold>Risk of driving and operating machinery</bold>
</p>
        <p>Patients who take difelikefalin may experience dizziness, somnolence, and mental status changes.&#x000a0;The possibility exists&#x000a0;that difelikefalin may impair the physical or mental abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Therefore, patients are advised not to drive or operate dangerous machinery until the effect of&#x000a0;difelikefalin on their ability to drive or operate machinery is known.</p>
        <p>
<bold>Dizziness, somnolence, mental status changes, and gait disturbances</bold>
</p>
        <p>Patients who take difelikefalin may experience mental status changes, dizziness, somnolence, and gait disturbances, including falls. However, these adverse reactions may subside over time with continued treatment. In clinical trials, more patients who received difelikefalin reported at least&#x000a0;1 of these adverse reactions compared to those who received a placebo. The incidence of somnolence was higher in patients aged 65 years and older&#x000a0;than those younger. Patients should use caution when taking difelikefalin with centrally-acting depressant medications, sedating antihistamines, and opioid analgesics.</p>
      </sec>
      <sec id="article-132588.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Supportive treatment for the more commonly experienced adverse effects of difelikefalin, including vomiting and diarrhea, will increase positive patient outcomes. The health care team must avoid dehydration, acid-base disturbances, or an electrolyte imbalance when managing patients receiving difelikefalin.&#x000a0;Clinicians should ensure adequate hydration status and assess patients with routine labs, administering electrolyte repletion as indicated.<xref ref-type="bibr" rid="article-132588.r1">[1]</xref>&#x000a0;If the adverse effect of dizziness is experienced in patients taking difelikefalin, fall risk measures must be taken to avoid injury, especially in older or frail patients. Opioid withdrawal symptoms were not observed after the cessation of treatment with difelikefalin.<xref ref-type="bibr" rid="article-132588.r11">[11]</xref></p>
      </sec>
      <sec id="article-132588.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>At supratherapeutic levels (15 mcg per mL), concern for respiratory depression or euphoric effects has not been demonstrated.<xref ref-type="bibr" rid="article-132588.r1">[1]</xref><xref ref-type="bibr" rid="article-132588.r10">[10]</xref>&#x000a0;Difelikefalin has been studied in rats and determined to cause diuresis by activating central kappa opioid receptors.<xref ref-type="bibr" rid="article-132588.r17">[17]</xref>&#x000a0;Mild to moderate hypernatremia has been reported at supratherapeutic doses of 1.0, 2.0, and 5.0 mcg per kg. Any induced electrolyte imbalance observed during treatment should be managed per the standard of care in conjunction with the termination of medication administration and identification of any additional etiologies for the electrolyte disturbance.&#x000a0; The adverse effects mentioned previously, including hypoesthesia, paresthesia, and somnolence, are self-limiting at supratherapeutic doses.<xref ref-type="bibr" rid="article-132588.r10">[10]</xref></p>
        <p>No documented antidote for difelikefalin is currently in use. Considering the reassuring safety profile, the lack of activity in the CNS, and the more common adverse effects of difelikefalin subsiding without intervention, the clinical utility of naloxone in suspected supratherapeutic or toxic levels of difelikefalin is unlikely to be relevant. Phase&#x000a0;3 double-blind, randomized, placebo-controlled clinical trials have been conducted to study the use of difelikefalin for up to 8&#x000a0;and 12 weeks. The potential long-term effects of difelikefalin&#x000a0;remain unclear.</p>
      </sec>
      <sec id="article-132588.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The utility of a selective peripheral kappa opioid receptor agonist in treating uremic pruritis is emerging.<xref ref-type="bibr" rid="article-132588.r11">[11]</xref>&#x000a0;Patients with end-stage renal disease requiring dialysis face many challenges in preserving their quality of life. A coordinated effort by the nephrologist, dialysis nursing staff, patient family members, and primary care&#x000a0;clinicians is necessary to address the uremic pruritis often experienced by these patients appropriately so that the negative impact on the patient is diminished.<xref ref-type="bibr" rid="article-132588.r18">[18]</xref>&#x000a0;Common practice can evolve from current therapy for uremic pruritis, which often&#x000a0;ineffectively utilizes antihistamines or involves off-label use of gabapentin.<xref ref-type="bibr" rid="article-132588.r19">[19]</xref><xref ref-type="bibr" rid="article-132588.r20">[20]</xref><xref ref-type="bibr" rid="article-132588.r21">[21]</xref>&#x000a0;</p>
        <p>Understanding the mechanism of difelikefalin and how it effectively addresses the nonhistaminergic pathway that causes uremic pruritus is essential for the healthcare team to ensure that itching and the associated emotional distress often experienced by patients requiring dialysis may appropriately be addressed.<xref ref-type="bibr" rid="article-132588.r19">[19]</xref><xref ref-type="bibr" rid="article-132588.r5">[5]</xref>&#x000a0;The&#x000a0;IV dosing of difelikefalin, typically 3 times a week in&#x000a0;IV bolus form&#x000a0;after&#x000a0;completing dialysis sessions, is logistically ideal, enhancing team performance and subsequent patient outcomes when rendering this treatment.<xref ref-type="bibr" rid="article-132588.r4">[4]</xref>&#x000a0;Further research clarifying the efficacy of difelikefalin in diabetes and end-stage renal disease patients would provide valuable insight for clinical decision-making as these conditions often co-exist.<xref ref-type="bibr" rid="article-132588.r22">[22]</xref><xref ref-type="bibr" rid="article-132588.r21">[21]</xref>&#x000a0;</p>
        <p>The opioid crisis facing the healthcare industry today&#x000a0;requires&#x000a0;the introduction of safer&#x000a0;postoperative pain medications with decreased abuse potential. Surgeons and primary care clinicians can initiate&#x000a0;IV or oral difelikefalin for patients with acute postoperative pain or sub-acute and chronic pain, without&#x000a0;significant concerns for lethal overdose or euphoric effects, even at supratherapeutic doses.<xref ref-type="bibr" rid="article-132588.r1">[1]</xref>&#x000a0;The extensive development of safer formulations of traditional oral opioid medications&#x000a0;for pain management without the risk of misuse potential demonstrates&#x000a0;a need that the novel difelikefalin oral formulation would fulfill&#x000a0;through widespread implementation by healthcare providers.<xref ref-type="bibr" rid="article-132588.r21">[21]</xref><xref ref-type="bibr" rid="article-132588.r1">[1]</xref><xref ref-type="bibr" rid="article-132588.r14">[14]</xref>&#x000a0;Trials are currently underway to test&#x000a0;difelikefalin for use in controlling postoperative pain; early results have shown promise regarding cost-effectiveness, clinical efficacy, and adverse event profile, but more research is necessary.<xref ref-type="bibr" rid="article-132588.r2">[2]</xref></p>
      </sec>
      <sec id="article-132588.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132588&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132588">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132588/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132588">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-132588.s11">
        <title>References</title>
        <ref id="article-132588.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The opioid crisis: a 21st century pain.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-286</page-range>
            <pub-id pub-id-type="pmid">29869649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thokala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hnynn Si</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Hernandez Alava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaufler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fotheringham</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.</article-title>
            <source>Pharmacoeconomics</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-466</page-range>
            <pub-id pub-id-type="pmid">36735201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gallieni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Alleviating symptoms in patients undergoing long-term hemodialysis: a focus on chronic kidney disease-associated pruritus.</article-title>
            <source>Clin Kidney J</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-40</page-range>
            <pub-id pub-id-type="pmid">36726430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipman</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Yosipovitch</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>549</fpage>
            <page-range>549-555</page-range>
            <pub-id pub-id-type="pmid">33190563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos-Alonso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maldonado Mart&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Villanueva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vaca Gallardo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bajo Rubio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Del Peso Gilsanz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ossorio Gonz&#x000e1;lez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Selgas Guti&#x000e9;rrez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pruritus in dialysis patients. Review and new perspectives.</article-title>
            <source>Nefrologia (Engl Ed)</source>
            <year>2021</year>
            <month>Mar</month>
            <day>08</day>
            <pub-id pub-id-type="pmid">33707097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Germain</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shirazian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhaduri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Munera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Menzaghi</surname>
                <given-names>F</given-names>
              </name>
              <collab>Trial Investigators</collab>
            </person-group>
            <article-title>Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.</article-title>
            <source>Kidney Int Rep</source>
            <year>2020</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>600</fpage>
            <page-range>600-610</page-range>
            <pub-id pub-id-type="pmid">32405581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bissonnette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nograles</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Munera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jebara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cirulli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goncalves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <collab>KOMFORT Trial Investigators</collab>
            </person-group>
            <article-title>Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Feb</month>
            <day>09</day>
            <volume>388</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-517</page-range>
            <pub-id pub-id-type="pmid">36780675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gunasekaran</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laxmi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jindal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Paroxysmal Neuropathic Pruritus in Patients With Chiari Malformation Type I: A Rare Phenotype.</article-title>
            <source>Pediatr Neurol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>140</volume>
            <fpage>65</fpage>
            <page-range>65-67</page-range>
            <pub-id pub-id-type="pmid">36652778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2022</year>
            <volume>271</volume>
            <fpage>275</fpage>
            <page-range>275-292</page-range>
            <pub-id pub-id-type="pmid">33296031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viscusi</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Torjman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Munera</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Stauffer</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Setnik</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bagal</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Clin Transl Sci</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>1886</fpage>
            <page-range>1886-1893</page-range>
            <pub-id pub-id-type="pmid">33982405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Menzaghi</surname>
                <given-names>F</given-names>
              </name>
              <collab>KALM-1 Trial Investigators</collab>
            </person-group>
            <article-title>A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Jan</month>
            <day>16</day>
            <volume>382</volume>
            <issue>3</issue>
            <fpage>222</fpage>
            <page-range>222-232</page-range>
            <pub-id pub-id-type="pmid">31702883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phan</surname>
                <given-names>NQ</given-names>
              </name>
              <name>
                <surname>Lotts</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Antal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernhard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>St&#x000e4;nder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-60</page-range>
            <pub-id pub-id-type="pmid">22504709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trachtenberg</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Collister</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rigatto</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in the treatment of uremic pruritus.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>465</fpage>
            <page-range>465-470</page-range>
            <pub-id pub-id-type="pmid">32740217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lagac&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jfri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Litvinov</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Netchiporouk</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Newer and Safer Kappa-Opioid Agonist for Your Patients With Uremic Pruritus.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2020</year>
            <season>Sep/Oct</season>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>525</fpage>
            <page-range>525-526</page-range>
            <pub-id pub-id-type="pmid">32426990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastogi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lerma</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2023</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>387</fpage>
            <page-range>387-400</page-range>
            <pub-id pub-id-type="pmid">37010031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Munera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bagal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCafferty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Menzaghi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goncalves</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.</article-title>
            <source>Kidney Med</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>8</issue>
            <fpage>100513</fpage>
            <pub-id pub-id-type="pmid">36039153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meariman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Sutphen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mercante</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kapusta</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway.</article-title>
            <source>Pharmacol Res</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>185</volume>
            <fpage>106470</fpage>
            <pub-id pub-id-type="pmid">36202183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>DJR</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin for the Treatment of Uremic Pruritus.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Jan</month>
            <day>16</day>
            <volume>382</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-290</page-range>
            <pub-id pub-id-type="pmid">31940704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manenti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Fiaccadori</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin in Hemodialysis Patients with Pruritus.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>21</day>
            <volume>382</volume>
            <issue>21</issue>
            <fpage>2064</fpage>
            <pub-id pub-id-type="pmid">32433846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin in Hemodialysis Patients with Pruritus.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>21</day>
            <volume>382</volume>
            <issue>21</issue>
            <fpage>2064</fpage>
            <page-range>2064-2065</page-range>
            <pub-id pub-id-type="pmid">32433847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fishbane</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin in Hemodialysis Patients with Pruritus. Reply.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>21</day>
            <volume>382</volume>
            <issue>21</issue>
            <fpage>2065</fpage>
            <page-range>2065-2066</page-range>
            <pub-id pub-id-type="pmid">32433848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132588.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brennan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davison</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Difelikefalin in Hemodialysis Patients with Pruritus.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>May</month>
            <day>21</day>
            <volume>382</volume>
            <issue>21</issue>
            <fpage>2064</fpage>
            <pub-id pub-id-type="pmid">32433845</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
